Articles On Telix Pharmaceuticals (ASX:TLX)

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Telix Pharmaceuticals has submitted a new drug application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer. Telix said subject t...

Telix (ASX:TLX) has announced the successful completion of CUPID, a first-in-human Phase 1 dose escalation study of TLX592 in patients with advanced prostate cancer.

I had the pleasure of joining Adam Keily on the ‘Equity Mates’ podcast, where we had a great discussion about ten noteworthy stocks that are currently catching my eye. These picks span across a variety of sectors, domestic and global and in...

The ASX200 slipped into the red at close, 0.05 of a per cent down with industrials gaining 0.49% and IT 0.27% doing the heavy lifting offset by communications limping over the line, shedding -2.5%. In the green Webjet (ASX:WEB) shot u...

It was a wild day for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Wednesday. After taking a bath yesterday, the ASX 200 had a strong start this mor...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Wednesday. In afternoon trade, the benchmark index is up 0.1% to 7,858.8 points. Four ASX shares that are rising more than most today are listed below. Here's why...

Seven S&P/ASX 200 Index (ASX: XJO) shares are leaping to 52-week highs today. Yep, seven! Their strong performance is helping lift the benchmark index 0.3% in early afternoon trade. Any guesses? Keep those in mind and read on. ASX 200...

The ASX200 closed just 12 points down (0.15%) as the local markets shrugged off another record close for the NASDAQ on Monday night. The IT and industrials sectors were strongest, both gaining just shy of 0.75%. Telecommunications fel...

It’s been a busy day at the Australian Energy Producers conference in Perth, where the morning’s guest speakers included resources minister Madeleine King and Woodside’s Meg O’Neill inside and several hundred protesters outside.  Apart f...

Telix says TLX592 is effective on prostate cancer Telix Pharmaceuticals (ASX:TLX) has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer. Th...

The Reserve Bank's May policy meeting minutes indicated that while raising the cash rate was considered if forecasts risked optimism regarding inflation factors, stronger-than-expected data prompted them to maintain the rate at 4.35%, citin...

The ASX200 closed around 0.63% up with energy soaring 2.3% and materials 1.9%. The poorest performer was healthcare – down 0.8%. In the green The Star Entertainment Group (ASX:SGR) shot up 20% on news it’s received interest fro...

The ASX200 is up 0.65% – in line with futures’ predictions.  Healthcare is down 0.4% – whilst materials is up 1.96% and energy 1.79% mid-session. The materials sector is having a strong run mid-session; Rio Tinto (ASX:RIO), Fortescue...

Telix Pharmaceuticals (ASX:TLX) announced on Monday it has filed early-stage paperwork proposing to US regulators a listing on the American equities markets. Morgan Stanley and Jefferies are among the firms acting as managers for the IPO...

Given the topic, let's try to keep this article as light-hearted as possible. Let's assume that one day, out of the blue, you get a call from a lawyer telling you that your mysterious great aunt Holga recently passed away at the ripe old ag...

Bell Potter says biotech very much a non-cyclical performer driven by catalysts including clinical trial data Radiopharmaceutical-focused Clarity Pharmaceuticals has risen 76% YTD after promising trial results Merchant Funds is bullish on...

Two ASX shares that have made their shareholders smile this year are DroneShield Ltd (ASX: DRO) and Telix Pharmaceuticals Ltd (ASX: TLX). Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a...

Australian shares closed higher on Tuesday, with the S&P/ASX 200 advancing 0.4% to 7664.1 points, supported by gains in lithium miners, while investors exercised caution ahead of the US Federal Reserve's policy meeting for insights into...

It was a mildly disappointing Wednesday for ASX investors today, with the S&P/ASX 200 Index (ASX: XJO) recording a slight loss. After spending most of the day in green territ...

  Companies discussed include: Telix Pharmaceuticals (ASX:TLX)Bank of Queensland (ASX:BOQ)MAAS Group Holdings (ASX:MGH)

One ASX healthcare stock is clocking a new record price today while the S&P/ASX 200 Index (ASX: XJO) struggles to keep its head above water. The Aussie share market is flailing this afternoon after the Australian Bureau of Statistic...

In the dynamic landscape of investing, uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts. Telix Pharmaceuticals (ASX:TLX), despite its relatively short tenure on the A...

ASX health stock fall in past five days in line with broader markets as economic and geopolitical factors weigh heavily ResMed falls as Eli Lily reports positive Phase 3 results of weight-loss drug in obese people with obstructive sleep ap...

It turned out to be a day of high relief for ASX investors, with the S&P/ASX 200 Index (ASX: XJO) finally recording a positive session after five days of falls in a row. By the c...

The S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Thursday. In afternoon trade, the benchmark index is up 0.6% to 7,650.2 points. Four ASX shares that are rising more than most today are listed below. Here's why th...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is taking off on Thursday morning. At the time of writing, the radiopharmaceuticals company's shares are up 15% to a record high of $14.46. Why is the Telix share price rocketing? Investo...

Telix Pharmaceuticals (ASX:TLX) has reported an 18 per cent increase in revenue for the first three months of the calendar year 2024.

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) fought hard but fell short at the final hurdle and slipped into the red. The benchmark index fell slightly to 7,605.6 points. Will the market be able to bounce back from this on Thursday?...

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary...

After shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down. At one stage the ASX was on track for its worst day in 13 months and at the close, real estate, consumer stocks and mining were all lickin...

The ASX200 has shed nearly double what futures predicted, trading down 2.05% All 11 sectors are in the red. Discretionary has lost the most so far, down 2.6%. Real Estate follows, down 2.305%, while in Canberra supermarket executives saw...

The S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Tuesday. In afternoon trade, the benchmark index is down a very disappointing 2.1% to 7,586.6 points. Four ASX shares that are avoiding the market selloff today are listed be...

Telix Pharmaceuticals (ASX:TLX) has been granted Fast Track designation by The United States Food and Drug Administration (FDA) for its brain cancer imaging software; TLX101-CDx (also known as Pixclara™). This Fast Track designation is s...

Telix Pharmaceuticals Ltd (ASX: TLX) shares are rising on Tuesday. In morning trade, the ASX 200 healthcare stock is up 1.5% to $13.08. Why is the ASX 200 healthcare stock pushing higher? Investors have been buying the company's shares afte...

The US FDA has granted fast-track designation to Telix Pharmaceuticals (ASX:TLX) investigational glioma imaging product Pixclara (TLX101-CDx).

The pain’s set to intensify today, with a 0.8 per cent fall predicted on the ASX200. Retail sales figures in the US came in better than expected, and with fears the Israel, Iran conflict could escalate, gold rose and so did bond yields....

FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy...

There could be some big returns on offer in the healthcare sector for Australian investors according to analysts. For example, the three ASX 200 healthcare stocks listed below have all been named as buys by analysts and tipped to deliver do...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) had a tough session and dropped into the red. The benchmark index fell 0.45% to 7,813.6 points. Will the market be able to bounce back from this on Friday and end the week on a high? Here...

The ASX200 is up nearly half a per cent – slightly beating futures predictions – with materials leading the charge into greener territory. Materials were up nearly 2 per cent in-mid-day trading with real estate and communications both d...

Telix Pharmaceuticals (ASX:TLX) has acquired one of its service suppliers – IsoTherapeutics Group – in a deal worth more than A$20 million. IsoTherapeutics, a commercial-stage entity, specializes in providing radiochemistry and bioconju...

The ASX200 is set to continue its upward run today, with futures pointing to a .41 per cent lift. US treasury yields climbed to the highest point in months on strong data, seeing the S&P500 and Dow Jones close a touch lower, while th...

The ASX200 has closed down .56 of a per cent with IT down 1.4 per cent and in the red for a second straight day, materials slumping 0.8 per cent and real estate shedding .61 per cent. Coming into sharp focus today were OncoSil Medical, T...

The S&P/ASX 200 Index (ASX: XJO)  wrapped up the shorter trading week on a sour note this Friday. After a fairly wild week, the index couldn't close in the green, giving investors a red...

The S&P/ASX 200 Index (ASX: XJO) is having a disappointing finish to the week. In afternoon trade, the benchmark index is down 0.7% to 7,760.9 points. Four ASX shares that are not letting that hold them back are listed below. Here's w...

Everyone remembers their first time. If you have never done it before, buying ASX shares can be a scary experience. You don't know whether you will lose money. You feel like you don't have as much knowledge as the veterans. You're concerne...

It was a very strong day indeed for the S&P/ASX 200 Index (ASX: XJO) this Thursday. After the disappointing session yesterday, it was back to the...

The S&P/ASX 200 Index (ASX: XJO) had a negative session this Wednesday, falling after an initially strong start to the week. Despite an early surge...

MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry soft...